Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A randomised, open-label study to compare the effect of new-onset therapy with PEGASYS [peginterferon alfa 2a], and continuation therapy with adefovir dipivoxil or lamivudine, on viral response in patients with chronic hepatitis B pre-treated with adefovir dipivoxil or lamivudine

Next Previous
Trial Profile

A randomised, open-label study to compare the effect of new-onset therapy with PEGASYS [peginterferon alfa 2a], and continuation therapy with adefovir dipivoxil or lamivudine, on viral response in patients with chronic hepatitis B pre-treated with adefovir dipivoxil or lamivudine

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 14 Mar 2016

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Peginterferon alfa-2a (Primary) ; Adefovir dipivoxil; Lamivudine
  • Indications Hepatitis B
  • Focus Therapeutic Use
  • Sponsors Roche

Most Recent Events

  • 23 Feb 2010 Planned number of patients changed from 140 to 14 as reported by Roche record.
  • 17 Jul 2008 New trial record.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top